Filed On Behalf Of:

Novartis AG and LTS Lohmann Therapie-Systeme AG

By:

Raymond R. Mandra ExelonPatchIPR@fchs.com (212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS INC. AND MYLAN PHARMACEUTICALS INC., Petitioners

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG, Patent Owners

Inter Partes Review No. 2014-00550¹

U.S. Patent 6,335,031

PATENT OWNERS' DEMONSTRATIVE EXHIBITS PURSUANT TO 37 C.F.R. § 42.70(b)

¹ Case IPR2015-00268 has been joined with this proceeding.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS INC. AND MYLAN PHARMACEUTICALS INC.,

Petitioners

۷.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG, Patent Owners

Inter Partes Review Nos. 2014-00550, 2014-00268


U.S. Patent 6,335,031

PATENT OWNERS' DEMONSTRATIVE EXHIBITS FOR ORAL HEARING

June 2, 2015

Professor Alexander M. Klibanov

- Professor of Chemistry and Bioengineering at M.I.T.
- Elected to the U.S. National Academy of Sciences
- Elected to the U.S. National Academy of Engineering
- Over 45 years as a practicing chemist
- Published over 300 scientific papers
- Given 370 invited lectures



Leo Recognizes That Discovery Of A Problem May Be A Patentable Invention

Paper 25 at 5, 7-8

1354

726 FEDERAL REPORTER, 3d S

(e.g., corticosteroids). See J.A. 6237. combined, or These researchers recognized possible advantages from combining a vitamin treatment with topical corticosteroids, but drug regimen where patients applied the drugs at different times of a day or on alternating days. See id. Moreover,

Although Dikstein and Serup attempt Serup recogn the combination of a vitamin D analog with problem, the a corticosteroid, neither discloses or adone of ordina dresses the stability problems of combinto improve u ing vitamin D analogs and corticosteroids using Turi. into one pharmaceutical formulation. As first have ne evidenced by the experiments Leo Pharlem, i.e., that maceuticals conducted, the prior art does Dikstein and not teach any composition that exhibits ble. To disc storage stable properties. Every example nary artisan disclosed in Dikstein contains either alseveral mont mond oil or propylene glycol. Similarly, tests. See '0 the examples disclosed in Serup contain 1, 56; see also not only water, but also almond oil, alcohol, recognizing t or propylene glycol. would an art

Leo Pharmaceuticals presented experiand attempt mental evidence to the Board that each of for storage s these ingredients harmed the storage staand advances bility of the vitamin D analog and corticoseasy, the rec teroid combination. See J.A. 562-64, 570 shown that (Hoy Decls. discussing propylene glycol have achieved and almond oil); J.A. 566-68 (Didriksen of Dikstein o Decl. discussing aqueous alcohol-based soltion does not vents). For example, the use of propylene ade glycol as a solvent resulted in 100% degra-Although t dation of the vitamin D analog. J.A. 562-564, 692-702. Similarly, the use of aque- positions with ous solvents resulted in almost complete ent claims] v degradation of the vitamin D analog after more storage three months of storage-98.3% degrada- mulated with tion in one formulation and 100% degrada- been used it tion in another. J.A. 710-16, 1025-26, went on to f And, when almond oil was used as a sol- "to overcome vent, vitamin D analogs degraded 13-29% ness." J.A. 10. Dy orusning aside in after three months of storage. J.A. 570, storage stability issue, the Board erred by

Moreover, because neither Dikstein nor Serup recognized or disclosed the stability problem, the record shows no reason for one of ordinary skill in the art to attempt to improve upon either Dikstein or Serup using Turi. The ordinary artisan would first have needed to recognize the problem, i.e., that the formulations disclosed in Dikstein and Serup were not storage stable.

vent, vitamin D analogs degraded 13-29% ness." J.A. <u>'10.</u> by orusmng assue me after three months of storage. J.A. 570, storage stability issue, the Board erred by 723-24. The vitamin D analogs were not nonly components at risk for degradation. When commercial ointments with vitamin D analogs or corticosteroids were reasons that a person of ordinary skill in

Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346, 1354 (Fed. Cir. 2013)

Omeprazole Recognizes That Discovery Of A Problem May Be A Patentable Invention

Paper 25 at 5

1380

536 FEDERAL REPORTER,

ings in various pharmaceutical prepara- omepraz tions in support of its argument that it Dr. Lan would have been obvious to one of skill in cle by the art to apply an inert subcoating to inventor Example 12 of the '495 European applica- provided tion. None of the references on which a person Apotex relies, however, undermine the tri- believed al court's conclusion that the claims of the ate a pr '230 and '505 patents would not have been omepraz obvious to a person of skill in the art. burg, C.

Apotex was required to show by clear lation of and convincing evidence that a person of Gastroer skill in the art would have appreciated the The Pill that "an need to include a subcoating in Example 12 of the '495 European application. The does not district court, however, found that the '495 dissoluti European application does not disclose or transpor suggest a negative interaction between the part of the sman mesune, oners me or drug core containing the magnesium omeprazole salt and the enteric coating in Ex- district court reasonably concluded that a ample 12. The court further found that a person person of ordinary skill in the art would not hav not have inferred from the '495 European ple 12 of application that a negative interaction teaching would occur. Based on those findings, the coating court concluded that a person of ordinary Even skill would have had no reason to apply a have re subcoating to the tablets shown in Exam-negative ple 12 of the '495 European application. coating To overcome that shortcoming of the court for '495 European application, Apotex relies obvious on testimony from Dr. Block that "[a] persubcoati son of ordinary skill would understand that problem cellulose acetate phthalate has free carbox- consider ylic acid groups and could interact with the would h omeprazole magnesium salt, the omepra- in the zole being acid-labile." The district court problem was presented with ample evidence to support the contrary conclusion, however. problem Dr. Langer, Astra's expert, testified that the ente the '495 European application does not art show suggest any problem relating to the inter- an alka action of the enteric coating and the drug pension core. Furthermore, Dr. Langer and Apo- bonate, tex's expert, Dr. Signorino, agreed that the tered w disclosure in the '495 European application applicat does not suggest any need to stabilize erburg,

Furthermore, Dr. Langer and Apotex's expert, Dr. Signorino, agreed that the disclosure in the '495 European application does not suggest any need to stabilize omeprazole beyond using the salt form.

possibilities." Based on that evidence, the

Based on that evidence, the district court reasonably concluded that a person of ordinary skill in the art would not have seen any need to apply to Example 12 of the '495 European application the teachings of the references disclosing subcoatings.

Was Rivastigmine Known Or Reasonably Suggested To Have An Oxidative Degradation Problem?

Paper 25 at 10-12, 13-44

The Art Taught That Rivastigmine Was Chemically Stable

• Enz (Ex. 1002)

• Enz 1991 (Ex. 2026)

• Rosin (Ex. 1008)

• Weinstock 1994 (Ex. 2027)

• Elmalem (Ex. 1009)

A POSA Would Not Reasonably Have Predicted That Rivastigmine Would Oxidatively Degrade Based On Its Structure

- Benzylic C-H bond and an adjacent tertiary amine (nicotine)
- Amines (Sasaki) (Ex. 1005)

A POSA Would Not Have Been Motivated To Combine Rivastigmine With An Antioxidant Unless Required

- Ebert (Ex. 1006)
- Handbook of Pharmaceutical Excipients (Ex. 1003)

Prior Art Reported Greater Chemical Stability Of Rivastigmine And RA7 And/Or Did No Add An Antioxidant

Paper 25 at 13-15, 21-22, 25-26, 27-28, 36

Enz (Ex. 1002)	Did not add an antioxidant to rivastigmine
Rosin	Did not add an antioxidant to RA ₇
(Ex. 1008)	RA ₇ 's greater in vivo activity over physostigmine "may be due to greater chemical stability"
Elmalem (Ex. 1009)	RA ₇ has "a greater chemical stability and longer duration of action than that of physostigmine"
Enz 1991	Did not add an antioxidant to rivastigmine
(Ex. 2026)	Rivastigmine "appears to have greater chemical stability than does physostigmine."
Weinstock 1994	Did not add an antioxidant to rivastigmine
(Ex. 2027)	"In animals and human subjects [rivastigmine] showed superior chemical stability than physostigmine."

Prior Art Reported Greater Chemical Stability Of Rivastigmine And RA7 And/Or Did No Add An Antioxidant

Paper 25 at 13-15, 21-22, 25-26, 27-28, 36

Reference	Did Not Add An Antioxidant To Rivastigmine/RA7	Reported Rivastigmine/RA7 Has Greater Chemical Stability Than Physostigmine
Enz (Ex. 1002)	✓	
Rosin (Ex. 1008)	✓	
Elmalem (Ex. 1009)		
Enz 1991 (Ex. 2026)	~	✓
Weinstock 1994 (Ex. 2027)		

Ex. 1002 at 19; Ex. 1008 at 3:37-39, 11:21-29; Ex. 1009 at 1; Ex. 2026 at 2; Ex. 2027 at 2-3; Ex. 2012 ¶¶ 47, 54, 68, 72, 74

A POSA Would Not Add An **Antioxidant Unless Required**

ing pharmaceutical produ-

. The commonly used ar include sodium sulfite, sod fite, sodium thiosulfate an

droethylglycine, citric, tart. EDTA has been used to st

cline, penicillin, epinephrir Reduction reactions are r

processes in pharmaceutic the reduction of gold, silver the corresponding free met

Paper 25 at 10-11

Remington's (Ex. 2017):

Obvious sources of pharmaceutical instability include the incompatibility of various ingredients within a formulation. Numerous examples are described in other sections of this book and the literature is replete with illustrations.

VER HEAVY METHINGS GUTTINE LIGHT MANUFACUTE, DACKAPIN In some instances it is necessary to use an ointment base that is less than ideal in order to achieve the required stability. For example, drugs that hydrolyze rapidly are more stable in a hydrocarbon base than in a base containing water, even though they may be more effective in the latter.

Incompatibility

Obvious sources of pharmaceutical instability include the incompatibility of various ingredients within a formulation. Numerous examples are described in other sections of this Oxidation may be inhil called negative catalysts. book and the literature is replete with illustrations. Thus, the subject need not be treated in detail here. diated chain reaction. TI oxidizable, act by possessir While undesirable reactions between two or more drugs

the active ingredient. The While undestrable reactions between two or more drugs are said to result in a "physical," "chemical" or "therapeu-tie" incompatibility, physical incompatibility is somewhat of a misnomer. It has been defined as a physical incompatibility winkly recognizable change. The latter may be in the form radation or act as chain ini ing an electron and receivi the activated molecule. The ideal antioxidant sh wide pH range, soluble in of a gross precipitate, haze or color change. toxic, nonvolatile, nonirrit tions, thermostable and co sure system and formulation

On the other hand, a chemical incompatibility is classified as a reaction in which a visible change does not occur. Since there is no visible evidence of deterioration, this type of there is no visible evidence of description, in supe of incompatibility requires that, knowledgeable personnel to recognize it, should it occur. A therapoutic incompatibility has been defined as an un-desirable pharmacological interaction between two or more ingredlents which leads to (10 potentiation of the therapeu-

ascorbyl-palmitate, hydrod drogualaretic acid, butylati droxyanisole and alpha-toc tic effects of the ingredients, (2) destruction of the effective Synergists, which increas generally organic compoun heavy metal ions (see Chaj ness of one or more of the ingredients or (3) occurrence of a toxic manifestation within the patient, vlenediamine tetraacetic

Oxidation-Reduction

Oxidation is a prime cause of product instability and of-ten, but not always, the addition of oxygen or the removal of hydrogen is involved. When molecular oxygen is involved. the reaction is known as autooxidation because it occurs spontaneously, though slowly, at room temperature. Oxidation, or the loss of electrons from an atom, frequent-

ly involves, free radicals and subsequent chain reactions. Only a very small amount of oxygen is required to initiate a chain reaction. In practice, it is easy to remove most of the oxygen from a container, but very difficult to remove it all. Hence, nitrogen and carbon dioxide frequently are used to Drugs containing an est hydrolysis. Some example

displace the headspace alt in pharmaceutical containers to help minimize deterioration by oxidation. As an oxidation reaction is complicated, it is difficult to the pH of the solution. A perform a hint study on conditive processes within a gen-stant and relatively easy to determine, can, however, provide

or storage. Hydronium and hydro tions. The rate of decomp ple, is more rapid in a r maximum stability (minir Ansel (Ex. 2020): pH 3.4. There is a pH rar antibiotic and vitamin p achieved by adding an acid. Al

The proper use of antioxidants involves their specific application only after appropriate biomedical and pharmaceutical studies. In certain instances other pharmaceutical additives have been found to inactivate a given antioxidant when used in the same formulation. In other cases certain antioxidants have been found to react chemically with the drugs they were intended to stabilize, without a noticeable change in the appearance of the preparation.

COLINA. OVINIPUONIS ASMAILY OCCU within minutes of ingesting or taking sulfited foods or drug products. Sulfiting agents covered by the regulations are potassium bisulfite, potassium metabisulfite, sodium bisulfite, sodium metabisulfite, sodium

ct chemically with the drugs they were ind to stabilize, without a noticeable change appearance of the preparation.

ause the stability of oxidizable drugs may versely affected by oxygen, certain pharmaals may require an oxygen-free atmoe during their preparation and storage. Oxmay be present in pharmaceutical liquids e airspace within the container or may be lved in the liquid vehicle. To avoid these sures, oxygen-sensitive drugs may be pre-I in the dry state and they, as well as liquid trations, may be packaged in sealed con-

ramers with the air replaced by an inert gas such as nitrogen. This is common practice in the commercial production of vials and ampuls of easily oxidizable preparations intended for parenteral

Trace metals originating in the drug, solvent,

A POSA Would Not Add An Antioxidant Unless Required

Paper 25 at 10-11

5. DEVELOPMENT PHARMACEUTICS

During the pharmaceutical development of the product the applicant should demonstrate:

- the necessity to add an antioxidant or a preservative to the finished product at the level chosen.
- the physical and chemical compatibility of the antioxidant and of the preservative with
 other constituents of the finished product, the container and the closures.

The concentration used must be justified in terms of efficacy and safety, such that the minimum concentration of preservative is used which gives the required level of efficacy. The appropriate test method for efficacy of antimicrobial preservation is that of the European Pharmacopoeia. This should be used to determine whether the required level of activity is

EMEA Guidelines (Ex. 2019): ^{at their use} te potential tspace gas.

In the case of antioxidants, these should only be used once it has been shown that their use cannot be avoided, even if the manufacturing process is optimised to minimise the potential for oxidation, for example by manufacturing and filling products under an inert headspace gas.

6. CONTROL OF THE EXCIPIENTS

Antimicrobial preservatives and antioxidants are defined as excipients and as such should be controlled following the guidance given in The Rules Governing Medicinal Products in the European Union, Volume III "Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product".

7. CONTROL OF THE FINISHED PRODUCT

The finished product release specifications should include an identification test and limits for any antioxidants and antimicrobial preservatives present in the formulation. The finished product specification against which the product is tested throughout its shelf-life should also include limits for the antimicrobial preservatives present.

Where antioxidants are used up during the manufacture of the product, the release limits should be justified by batch data. The adequacy of specified limits should be justified on the

3/4

CPMP/CVMP/QWP/115/95

NOVARTIS EXHIBIT 2019 Noven v. Novartis and LTS Lohmann IPR2014-00550 Page 4 of 5

Ex. 2019 at 4; Ex. 2012 at ¶ 40

Petitioners Fail To Consider Elmalem And The Prior Art As A Whole

Paper 25 at 29-31

sis,

ESTHER ELMALEM et al.

Each of the following drugs, physostigmine, (0.05 and 0.1 mg/kg); RA6 (0.5 and 1 mg/kg); RA7 (1 and 2 mg/kg) and RA15 (0.25 and 0.5 mg/kg), was injected intravenously (i.v.) with morphine (8 mg/kg) to groups of 6-10 rabbits per drug. Nine other rabbits were given morphine alone with 0.1 ml/kg saline. An significant fall in respiration rate of about 50% and additional group of 6 rabbits received morphine a rise in paCO₂ of 54% within 15 min, which lasted

Antagonism of the respiratory depressant effect of morphine by antiAChE Intravenous injection of morphine (8 mg) caused a antly reduced from

DESULTS.

n, while the pH fell Elmalem (Ex. 1009): dt 15-60 min. Mor-by 70-120 beats per d caused a small

mificant decrease in blood

All drugs were made up freshly in sterile saline, which included an equal weight of sodium metabisulphite, to prevent oxidation.

homogenized in phosphate buffer (0.1 M) pH 8, cholinergic hyperactivity, including salivation, defaecontaining 1% Triton. The mixture was centrifuged at 1000 g and the supernatant, which contained most of the solubilized enzyme, was used for the determination of the activity of AChE by the method of Eliman, Courtney, Andres and Featherstone (1961). At a dose of 0.5 mg, both the change in paCO₂ and The percentage inhibition of AChE by the drugs was computed by comparison with the pooled mean value for each of the appropriate saline-treated con-

cation and slight muscular twitches. The drug RA13 (0.25 mg) significantly reduced the

elevation in paCO₂ and the fall in respiratory rate after morphine, only at 15 min after injection (Fig. 2). in respiration rate, induced by morphine, were significantly antagonised for 3 hr (Fig. 2) but the brady

Estimation of plasma cholinesterase

Blood (0.5 ml) was withdrawn into a heparinized syringe, during the control period and at 5, 15, 30, 60, 90, 120, 150 and 180 min after injection of the AChE inhibitors. The blood was centrifuged at 4°C for 5 min at 1000 g and the activity of AChE of the plasma was measured by the method of Ellman et al. (1961).

Drugs

The agents tested were RA, (N-ethyl-3[1-(dimethylamino)ethyllphenyl carbamate) HCl. RA, (N-ethyl, N-methyl-3[1-(dimethylamino)ethyl) phenyl carbamateHCl. RA15(N-propyl-3(1-dimethylamino)-ethyl]phenyl carbamate HCl. Physostigmine salicylate (Sigma Ltd); Morphine HCl (Teva Pharmaceuticals, Israel). All drugs were made up freshly in sterile saline, which included an equal weight of sodium metabisulphite, to prevent oxidation. All doses are expressed as mg per kg of body weight of the appropriate salt.

Iding Privso.ting Privso.com \$ 20 TIME AFTER INJECTION HOURS Fig. 1. The influence of physostigmine on the respirator depressant effect of morphine. Physostigmine was injected intravenously at the same time as morphine. "Significantly rphine alone, P < 0.05. Noven Ex. 1009 different from mo Page 2 of 6

Physostigmine Was Known To Undergo Hydrolysis

Paper 25 at 31

Rosin (Ex. 1008):

This application is a continuation of a No. 185,451, filed on 04/25/88, entitled I mates which in turn was a continuation Ser. No. 835,466 filed Mar. 3, 1986, bot

1 PHENVI, CARRAMATES

doned. The present invention relates to novel mates which are useful as pharmaceutical The invention further relates to pharmace sitions having anticholinesterase activity. Acetylcholine is a major neurotransm found in all parts of the body. Any reactivity, either as a result of neuronal dam ation etc. or as induced by drugs or 1 marked changes in the function of the or tylcholine itself has an extremely short ha is rapidly hydrolysed at its site of action by specific cholinesterase enzymes. Drug acetylcholinesterase, markedly increase the action of acetylcholine, thereby enhanced gic transmission. Three such agents are u i.e., physostigmine, a naturally occurring two synthetic analogues, neostigmine ar mine. The latter two agents are strongly ic iological pH and therefore are only por from the gastro-intestinal tract, and do not central nervous system to any significant e stigmine is absorbed after oral admin readily enters the brain. As a therapeuti several disadvantages. It is chemically must be prepared in solution with an an must be prepared in solution with an any protected from light. It has a relatively short half-life 35 tubocurarine, an antagonist of acety/choline. The sec-

(20-40 mins) thereby necessitating frequent administration. The latter is of particular importance when the drug is to be administered chronically. It has a low

therapeutic ratio, a value of majority of studies in labora therapeutic window, i.e. sma can be given without the acc Although physostigmine is intestinal tract, this is report predictable, and therefore i ninister the drug parenteral back if it is to be used chroni-There are a number of clin ditions which are associate activity which can be improv an anticholinesterase agent. cholinergic transmission ind nous substances acting in th yous system. Peripherally ac d-tubocurarine and pancuro

muscle relaxants. Their action can readily be overcome by an anticholinesterase drug. Drugs which interfere with central cholinergic transmission are numerous. anticholinergic, atropine-like drugs including antiparkinson drugs, tricyclic antidepressants, neuroleptics, 60 employed as pharmaceuticals all contain a charged opiate analgesics, benzodiazepines and some types of nitrogen function and can be broadly classified into general anaesthetics. So far the only agent that has proved to be of any value in reversing the effects of the latter group of drugs is physostigmine. In all reported cases of drug overdose or lack of recovery when the 65 agent was used peri-operatively, physostigmine is usu-ally administered parenterally, and administration is ted every 20-30 minutes as required.

stigmine is absorbed after oral administration and readily enters the brain. As a therapeutic agent it has several disadvantages. It is chemically unstable and must be prepared in solution with an antioxidant, and protected from light.

ond group consists of various organophosphorus compounds, such as disopropylfluorophosphonate, paraxon etc. The vast majority of the compounds of both these

The

Physo-

30

35

monomethyl derivatives tend to be unstable in solution and hydrolyse readily at physiological pH.

opste, a quaternary ammonium organophosphorus compound, employed in eye drops for the treatment of glaucoma.

The synthetic anticholinesterase agents currently nitrogen function and can be broadly classified into 3 groups. (1) Reversible inhibitors which contain a charged gn


nitrogen function attached to an aromatic ring, e.g. edrophonium. (2) Dimethyl carbamates with an aromatic or hetero cyclic ring containing a charged nitrogen, neostigmine, pyridostigmine

> Noven Ex. 1008 Page 2 of 8

Ex. 1008 at 1:32-34, 2:45-47; Ex. 2012 at ¶¶ 78, 82

An Antioxidant Prevents The Oxidation Of Physostigmine's Hydrolytic Degradant

Paper 25 at 31



Ex. 2038 at 3; Ex. 2012 at ¶¶ 84-85

Elmalem States That RA₇ Has Greater Chemical Stability Than Physostigmine

Paper 25 at 28

Neuropharmacology Vol. 30, No. 10, pp. 1059-1064, 1991 Printed in Great Britain. All rights reserved 0028-3908/91 \$3.00 + 0.00 Copyright @ 1991 Pergamon Press pl ANTAGONISM OF MORPHINE-INDUCED RESPIRATORY DEPRESSION BY NOVEL ANTICHOLINESTERASE Elmalem (Ex. 1009): Denartmen laminoethyl-r morphine in nhysostigmin attempt to overcome these drawbacks, a number of to groups of was measured rabbits, which mornhine, in novel anticholinesterase agents were synthesized in The drugs R. depression, wi inhibition of the former a It is sugge this laboratory. These agents readily penetrate the respiratory de Key wordscentral nervous system, have a greater chemical stab-In previous studies i tal animals it was reduce the respirato ility and longer duration of action than that of without interfering (Snir-Mor, Weinsto Weinstock, Erez Davidson, Rosin an potential therapy f physostigmine and several of them also have signifireceiving opiates, r cantly higher therapeutic ratios (Weinstock, Razin,

serious disadvantage its relatively high appearance of distr doses (Christie, She Its low chemical stal also necessitate fr attempt to overcom Chorev and Tashma, 1986). novel anticholineste this laboratory. Th central nervous syst ility and longer di physostigmine and several or mem also have signifi-Chorev and Tashma, 1986). Address correspondence to Professor Marta Weinstock, Department of Pharmacology, The Hebrew University Hadassah Medical School, Jerusalem 91010, Israel.

cantly higher therapeutic ratios (Weinstock, Razin, counted visually for periods of 30 sec. Blood gases and nH were measured on a blood gas analyzer (Instrumentation Laboratories) after correction for the appropriate body temperature from samples of blood taken from the ear artery. Blood pressure and heart rate were monitored on a Brush Gould recorder.

Noven Ex. 1009 Page 1 of 6

1059

In

an

Elmalem Quantitatively Compared The Effects Of Different Drugs On Morphine-Induced Respiratory Depression

Paper 25 at 28

Neuropharmacology Vol. 30, No. 10, pp. 1059-1064, 1991 Printed in Great Britain. All rights reserved 0028-3908/91 \$3.00 + 0.00 Convright @ 1991 Pergamon Press pl ANTAGONISM OF MORPHINE-INDUCED RESPIRATORY DEPRESSION BY NOVEL ANTICHOLINESTERASE AGENTS MARTA WEINSTOCK ** Elmalem (Ex. 1009): MARTA WEINSTOCK^{1*}, School of Pharmacy, Hebrew University, Israel

Summary-This study compared the effects of 3 novel antiAChE agents (derivatives of dimethylaminoethyl-phenyl carbamate) with that of physostigmine on the respiratory depression induced by morphine in rabbits. Each drug, RA_{6} (1 mg i.v., 2 mg s.c.) RA_7 (1 or 2 mg i.v.); RA_{15} (0.25 or 0.5 mg i.v.), physostigmine (0.05 or 0.1 mg i.v.) or saline (1 ml), was injected simultaneously with morphine (8 mg i.v.) to groups of 6-10 rabbits.

In previous studies in human subjects and experimental animals it was shown that physostigmine could reduce the respiratory depressant effect of morphine, without interfering with the analgesic effect (Snir-Mor, Weinstock, Bahar and Davidson, 1983; Weinstock, Erez and Roll, 1981a; Weinstock, Davidson, Rosin and Schnieden, 1982). However, as potential therapy for concomitant use in patients receiving opiates, physostigmine has a number of serious disadvantages. The most important of these is its relatively high toxicity, which results in the appearance of distressing side effects at therapeutic doses (Christie, Shering, Ferguson and Glenn, 1981). Its low chemical stability and short duration of action also necessitate frequent administration. In an attempt to overcome these drawbacks, a number of novel anticholinesterase agents were synthesized in prepared with catheters in the central ear artery and this laboratory. These agents readily penetrate the marginal car vein, as previously described (Weinstock central nervous system, have a greater chemical stab- et al., 1981a). Rectal temperature was monitored on ility and longer duration of action than that of a telethermometer with the aid of a thermistor probe physostigmine and several of them also have significantly higher therapeutic ratios (Weinstock, Razin, Chorev and Tashma, 1986).

*Address correspondence to Professor Marta Weinstock, Department of Pharmacology, The Hebrew University Hadassah Medical School, Jerusalem 91010, Israel.

1059

The purpose of this study was twofold; to compare the abilities of three of these novel anticholinesterase agents with that of physostigmine to antagonize the respiratory depressant effect of morphine and to determine whether there is a correlation between the degree of such antagonism and the amount of inhibition of acetyl-cholinesterase (AChE) in the medulla oblongata

METHODS

Antagonism of the cardiovascular and respiratory depressant effects of morphine by the anticholinesterase compounds

Male and female rabbits, weighing 2.5-3 kg, were inserted into the rectum. Respiration rate was counted visually for periods of 30 sec. Blood gases and nH were measured on a blood gas analyzer (Instrumentation Laboratories) after correction for the appropriate body temperature from samples of blood taken from the ear artery. Blood pressure and heart rate were monitored on a Brush Gould recorder.

Noven Ex. 1009 Page 1 of 6

Elmalem Was A Well-Controlled Study

Paper 25 at 28-29, 32

Neuropharmacology Vol. 30, No. 10, pp. 1059-1064, 1991 Printed in Great Britain. All rights reserved

0028-3908/91 \$3.00 + 0.00 Copyright © 1991 Pergamon Press plc

Page 1 of 6

ANTAGONISM OF MORPHINE-DEPRESSION BY NOVEL AI AGENT

ESTHER ELMALEM,¹ M. CHOREV² ar ¹Departments of Pharmacology and ³Medicinal Chemist Ein Kerem, Jerusale

(Accepted 13 May

Summary—This study compared the effects of 3 now laminesthy-phenyl carbanates, with that of physosigiam morphine in rabbits. Each drug, $RA_{\rm eff}$ (ing i.v., $2 \, {\rm mg}$ s.c.) physosigiamic (0.05 or 0.1 mg, i.v.) or sainic (11 mg), vas inj to groups of 6-10 rabbits. Respiration rate, blood gases was measured before and at 15 min intervais alter injecti rabbits, which were sacrificed at the time of maximal ant morphine, in order to measure the activity of AChE in 1 Physosigiamice (0.1 mg) only antagonized the increase in The drugs RA, (0.5 mg), RA, (2.5 mg) and RA, (2 mg depression, without obvious signs of peripheral choilenerg relationship between the deprec of antagonism of the efinhibition of ChE in plasma. In contrast, a highly signifithe former and the amount of inhibition of AChE in th-Its suggested that the novel carbamates may have porespiratory depression of opiates, without impairing and

Key words-respiratory depression, cholinesterase inhibit

In previous studies in human subjects and experimental animals it was shown that physostigmine could the reduce the respiratory depressant effect of morphine, without interfering with the analgesic effect res (Snir-Mor, Weinstock, Bahar and Davidson, 1983; det Weinstock, Erez and Roll, 1981a; Weinstock, Davidson, Rosin and Schnieden, 1982). However, as potential therapy for concomitant use in patients receiving opiates, physostigmine has a number of serious disadvantages. The most important of these is its relatively high toxicity, which results in the appearance of distressing side effects at therapeutic An doses (Christie, Shering, Ferguson and Glenn, 1981). Its low chemical stability and short duration of action CON also necessitate frequent administration. In an attempt to overcome these drawbacks, a number of novel anticholinesterase agents were synthesized in pre this laboratory. These agents readily penetrate the ma central nervous system, have a greater chemical stabet ility and longer duration of action than that of ate ins physostigmine and several of them also have signifi-COL cantly higher therapeutic ratios (Weinstock, Razin, and Chorev and Tashma, 1986). (In

*Address correspondence to Professor Marta Weinstock, Department of Pharmacology, The Hebrew University Hadassah Medical School, Jerusalem 91010, Israel. rec

the

1059

Formulation Controls:

• All drugs formulated with an antioxidant

Route Of Administration Controls:

All drugs administered by injection

Test Subject Controls:

- At least 4 rabbits/treatment
- All rabbits similar size (2.5 to 3 kg)
- Dosages calculated per kg body weight
- Blood samples analyzed before treatment
- Changes in body temperature monitored
- Differences in respiration rates normalized

Ex. 1009 at 1-2; Ex. 2012 at ¶¶ 99-103

Weinstock 1994 Did Not Suggest That Rivastigmine Requires An Antioxidant In Any Formulation

Paper 25 at 36

Weinstock 1994 (Ex. 2027):

J Neural Transm (1994) [Suppl] 43: 219–225 © Springer-Verlag 1994

Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors

M. Weinstock¹, M. Razin¹, M. Chorev², and A. Enz³

esterase. If memory impairments in AD are related to a lack of cholinergic activity in cortical and hippocampal brain areas, SDZ ENA 713 should produce significant symptomatic improvement.

Introduction

Summary. The pharmacological and clinical properties of a novel phenyl carbamate acetylcholinesterase (AChE) inhibitor, SDZ ENA 713 are described. In animals and human subjects this compound showed superior chemical stability, oral bioavailability and a longer duration of action than physostigmine.

NOVARTIS EXHIBIT 2027 Noven v. Novartis and LTS Lohmann

PR2014-00550

Petitioners' Reading Of Elmalem Adds A Variable To The Well-Controlled Study

Paper 25 at 33-34

Elmalem (Ex. 1009):

Each of the following di and 0.1 mg/kg): RA. (0.5 a 2 mg/kg) and RA15 (0.25 an intravenously (i.v.) with groups of 6-10 rabbits per were given morphine alone additional group of 6 ra (8 mg/kg) plus RA6, (2. (s.c.). Blood samples were t sis, at least twice before ada and 30 min after injection intervals, for 3 hr.

Measurement of anticholine areas of the brain of rabbit

Rabbits were injected i physostigmine or each of doses designated, or with F 4 animals was used for e stated times after the inje sacrificed by air embolism were injected with saline or sacrificed at the same times the anticholinesterases, i.e. each after 15 and 30 min. T the frontal cortex, hippoci rapidly dissected out on ice. homogenized in phosphat containing 1% Triton. The at 1000 g and the supernata

of the solubilized enzyme, was used for the determination of the activity of AChE by the method of Eliman, Courtney, Andres and Featherstone (1961). At a dose of 0.5 mg, both the change in paCO₂ and The percentage inhibition of AChE by the drugs in respiration rate, induced by morphine, were signifiwas computed by comparison with the pooled mean cantly antagonised for 3 hr (Fig. 2) but the bradyvalue for each of the appropriate caline treated controis

Estimation of plasma cholin Blood (0.5 ml) was with syringe, during the control j plasma was measured by th (1961).

Drugs

The agents tested were R

amino)ethyllphenyl carbamawy river por N-methyl-3[1-(dimethylamino)ethyl] phenyl carbamateHCl. RA15(N-propyl-3(1-dimethylamino)-ethyl]phenyl carbamate HCl. Physostigmine salicylate (Sigma Ltd); Morphine HCl (Teva Pharmaceuticals, Israel). All drugs were made up freshly in sterile saline, which included an equal weight of sodium metabisulphite, to prevent oxidation. All doses are expressed as mg per kg of body weight of the appropriate salt.

Each of the following drugs, physostigmine, (0.05) and 0.1 mg/kg); RA_6 (0.5 and 1 mg/kg); RA_7 (1 and 2 mg/kg) and RA₁₅ (0.25 and 0.5 mg/kg), was injected intravenously (i.v.) with morphine (8 mg/kg) to groups of 6-10 rabbits per drug. Nine other rabbits were given morphine alone with 0.1 ml/kg saline.

elevation in paCO₂ and the fall in respiratory rate after morphine, only at 15 min after injection (Fig. 2).

All drugs were made up freshly in sterile ⁵ ⁽¹⁾ ⁽ metabisulphite, to prevent oxidation.


> # 25 TIME AFTER INJECTION HOURS Fig. 1. The influence of physostigmine on the respirator depressant effect of morphine. Physostigmine was injected intravenously at the same time as morphine. "Significantly rphine alone, P < 0.05. Noven Ex. 1009 different from mo Page 2 of 6

35

Antioxidant Amount Is Not Calculated Based On The Amount Of Drug

Paper 42 at 9-10; see also Paper 25 at 33-34


Dr. Kydonieus (Ex. 1049):



Ex. 1049 at 59:9-20; see *also* Ex. 2012 at ¶ 110

Elmalem And Weinstock 1981 Studies Were Conducted For Different Purposes

Paper 25 at 34-35 n.7



Ex. 1009 at 1; Ex. 2046 at 1; Ex. 2012 at ¶¶ 112-16

Elmalem And Weinstock 1981 Used Different Experimental Designs

Paper 25 at 34-35 n.7; Paper 42 at 10-11

ESTHER ELMALEM et al.

Each of the following drugs, physostigmine, (0.05 and 0.1 mg/kg); RA6 (0.5 and 1 mg/kg); RA7 (1 and 2 mg/kg) and RA15 (0.25 and 0.5 mg/kg), was injected intravenously (i.v.) with morphine (8 mg/kg) to and of 6 10 antibits and down Nilms ather

DESULTS. Antagonism of the respiratory depressant effect of morphine by antiAChE Intravenous injection of morphine (8 mg) caused a all in respiration rate of about 50% and

CO2 of 54% within 15 min, which lasted Elmalem (Ex. 1009): The paO₂ was significantly reduced from 5 ± 5 at 15 and 30 min, while the pH fell 0.007 to 7.27 ± 0.01 at 15-60 min. Mor-

All drugs were made up freshly in sterile

saline, which included an equal weight of sodium

25 µ/ml of heparin. Blood pressure and heart rate were recorded on a injection of 4 and 10 mg/kg of morphine respectively. The peak Brush Gould recorder by means of a transducer attached to one arterial cannula. Drugs were administered through a butterfly needle (no. 23) placed in a marginal ear yein. Physostigmine or neostigmine was infused i.v. in a volume of 0.09 ml/min by means of a Harvard constant infusion

Rectal temperature was monitored on a telethermometer (Yellow Springs Instrument Company, Yellow Springs, OH) with the aid of a thermistor probe inserted into the rectum. Respiration rate was counted visually and blood gases and pH were measured on Corning automatic blood gas analyzer after adjustment to the appropriate body temperature

505

Physostigmine Antagonism of Morphine

hypotensive response $(9.8 \pm 2.2 \text{ and } 12.4 \pm 1.8 \text{ mm Hg})$ occurred 20 to 30 min after injection of 2 and 4 mg/kg, respectively. The response to 10 mg/kg of morphine was inconsistent, with some rabbits displaying a rise of 5 to 10 mm Hg during the first 10 min and others, a small nonsignificant fall. Both the bradycardia and hypotensive response to 4 mg/kg of morphine lasted 2.5 to 3 hr

A dose of 4 mg/kg of morphine was therefore chosen for all subsequent experiments since it produced the most extensive and consistent vasodepression and bradycardia.


Pretreatment with ATMN (0.5 mg/kg) completely prevented the bradycardia and reduced the fall in blood pressure

Morphine (4 mg/kg) caused more than a 50% reduction in respiratory rate, which was associated with a 48% increase in arterial Paco.. Blood pH was reduced from 7.40 to 7.24 (see fig. 1). Maximum respiratory depression occurred between 30 and 60 min after morphine administration and lasted 3 hr.

A considerable degree of analgesic activity was also seen at this dose level, 30 min after injection of morphine, with most of the rabbits failing to respond to the highest degree of pressure (table 1).

Naloxone, given by continuous i.v. infusion at a dose of 0.1 mg/min completely prevented all the above effects of morphine (4 mg/kg) in four rabbits.

Influence of anticholinesterase agents on actions of



the frontal cortex, hippocampus and medulla were rapidly dissected out on ice, weighed individually and homogenized in phosphate buffer (0.1 M) pH 8, cholinergic hyperactivity, including salivation, defaecontaining 1% Triton. The mixture was centrifuged at 1000 g and the supernatant, which contained most of the solubilized enzyme, was used for the determi-elevation in paCO₂ and the fall in respiratory rate nation of the activity of AChE by the method of after morphine, only at 15 min after injection (Fig. 2).

inhibition of AChE by the drugs

cardia induced by morphine at 15 and 30 min. These effects were accompanied by signs of peripheral cation and slight muscular twitches.

metabisulphite, to prevent oxidation.

The drug RA13 (0.25 mg) significantly reduced the Ellman, Courtney, Andres and Featherstone (1961). At a dose of 0.5 mg, both the change in paCO; and

Weinstock 1981 (Ex. 2046):

Estimation of plasma chounesterase

infusion of physostigmine, and at 30, 60 and 90 min after injection of morphine. The volume of blood taken was replaced each time with an equal volume of sterile saline. In five rabbits, neostigmine (2.5 µg/kg/ min) was infused for 30 min and then continued after injection of morphine (4 mg/kg). Blood pressure, heart and respiration rates and blood gases were measured as above. In six other rabbits, ATMN (0.5 mg/kg), or in four animals, hyoscine (10 mg/kg), was given, 15 min before the infusion of physostigmine, 5 µg/kg/min.

In four rabbits, naloxone was infused i.v. at a concentration of 0.1 mg/kg/min for 15 min before and for 90 min after injection of 4 mg/kg of morphine. Blood pressure, heart and respiration rates were recorded as described above

Estimation of plasma cholinesterase. Blood (0.3-0.5 ml) was withdrawn into a heparinized syringe during the predrug control period and at 30 and 60 min after commencement of physostigmine infusion (i.e. 30 min after morphine injection). The blood was centrifuged

Morphine and physostigmine were made up freshly for each experiment in sterile saline which included an equal weight of ascorbic acid to prevent oxidation.

(Sigma Ltd); Morphine HCl (Teva Pharmaceuticals, Israel). All drugs were made up freshly in sterile saline, which included an equal weight of sodium metabisulphite, to prevent oxidation. All doses are expressed as mg per kg of body weight of the appropriate salt.

TIME AFTER INJECTION HOURS Fig. 1. The influence of physostigmine on the respiratory depressant effect of morphine. Physostigmine was injected intravenously at the same time as morphine. "Significantly different from morphine alone, P < 0.05. Noven Ex. 1009

Page 2 of 6

Effect of morphine on blood pressure, heart rate, res-Morphine (4 piration and pain threshold. Intravenous injection of morphine (2 mg/kg) caused significant bradycardia (reduction of min 30 mi 72 ± 10 beats/min) within 5 min, whereas 1 mg/kg only reduced Physostiami min, 30 m heart rate by 30 ± 9 beats at 60 min. Reductions in heart rate (4 mg/kg) of 108 ± 12 and 102 ± 10 beats/min occurred 5 to 30 min after

	21	1.38 ± 0.13
mg/kg)	9	4.55 ± 0.24
ne (5 μg/kg/ in)	7	1.71 ± 0.28
ne (5 µg/kg/ n) + morphine	12	4.91 ± 0.08

NOVARTIS EXHIBIT 2046 Noven v. Novartis and LTS Lohmann IPR2014-00550 Page 2 of 5

Ex. 1009 at 2; Ex. 2046 at 2; Ex. 2012 at ¶¶ 117-18

Rosin Discloses Millions Of "Compounds Of The Invention"

Paper 25 at 24-25

Rosin (Ex. 1008):

4,948,807

be given tog

There is :

cerbating th

carbamates malian brain

activity, e.g.

Thus acc

provided a p duce antich

system of

general for

Especial

been descr

tuted deriv

Re=CH1

30

35

45


Accordin

suffering fr

tics and ger stay of patie There is a (3) Bisquaternary structures, e.g. Demacarium, Amenonium. These agents tend to be more selective abibitors of acetylcholinesterase than butyrylse, compared nary molecules The pharmaceutical application of the quaternary

tive, or due anticholinesterase agents is limited because of their poor side effects netration through cell membranes. They are therenation and fore used for actions outside the central nervous system. with narcot and are usually given parenterally, since they are not reliably absorbed from the gastrointestinal tract. Edrotency. phonium, neostigmine and pyridostigmine and the bisbe given t quaternary analogues are used in anesthetic practice for which have the reversal of the action of muscle relaxants. They are diminish or also used for the treatment of myasthenia gravis, and paralytic ileus. Physostigmine is the only potent anti-cholinesterase surprisingly

agent which has been used clinically to treat conditions in which an elevation of brain acetylcholine activity is desired. These include, Alzheimer's disease, tardive dyskinesia, Down's syndrome and Huntingdon's chorea. Physostigmine is also used to reverse the effects of overdose of anticholinergic agents, anti-Parkinson drugs, benzodiazepines and opiate analgesica. ostigmine is a natural alkaloid extracted from 25 alabar beans and the seeds of the vine Physostigma




There is a need to provide new carbamate derivatives which show greater chemical stability than physostig-

Furthermore there is a need to provide new com- pounds which inhibit acetylcholinesterase in the brain	40	R ₁ is hydr zyl,
for periods exceeding 3 hours but not more than 12		R ₂ is hyd
hours after a single administration.		R1 and R
There is also a need to provide new compounds		are atta
which will be completely and reliably absorbed after	45	cal,
oral administration.		R ₃ is hyd
There is also a need to provide new compounds		R4 and R
which will be relatively less toxic than physostigmine.		lower a
This means that the therapeutic ratio, defined as		the me
	50	or a pharm
		physiologic
dose to produce therapeutic effect dose to produce mortality in 50% of animals		these comp

should be significantly higher than those of physostigmine and that the incidence and severity of side effects tions bavin should be less than those of physostigmine at therapeunervous sys tic doses. alkyl group both methy

- There is also a need to provide new compounds which can be given orally or parenterally to treat chronic conditions in which it is desired to raise cholin-Certain c 60 have previo ergic activity in the central nervous system. These incompound R5=methy clude, Alzheimer's disease, Down's syndrome, Hun-tingdon's chorea, Friedrich's ataxia. to be an in There is also a need to provide compounds that can drops. The
- be given parenterally at the end of operations, and anes- 65 R3 are met thetic procedures, to restore wakefulness, respiration and cardiovascular parameters to normal, after the use cholinergic, opiates, benzodiazepines, neu

Thus according to the present invention there is now provided a pharmaceutical composition adapted to produce anticholinesterase activity in the central nervous system of mammals comprising a compound of the 25 general formula I



these compounds are called compounds of the invention.

Ŧ

wherein

- R1 is hydrogen, lower alkyl, cyclohexyl, allyl or benzyl,
 - R₂ is hydrogen, methyl, ethyl or propyl, or
 - R_1 and R_2 together with the nitrogen to which they are attached form a morpholino or piperidino radical,
 - R₃ is hydrogen or lower alkyl,
 - R4 and R5 are the same dr different and each is a lower alkyl, and the dialkylaminoalkyl group is in the meta, ortho or para position,
- 50 or a pharmacologically acceptable salt thereof and a physiologically acceptable carrier therefor. Hereinafter these compounds are called compounds of the invention.

Ex. 1008 at 4:21-53; Ex. 2012 at ¶ 63

Hereinafter

Rosin Discloses Compositions For Oral And Parenteral Administration

Paper 25 at 25

4,948,807

stir at ambient temperature for 15-24 hours. Removal of of procedures as well as of the principles and concepthe acetonitrile under reduced pressure (20 mm Hg) is followed by the addition of water (10-25 mi). The nH of the aqueous solution is adjusted to pH=11 by the addi tion of the appropriate amount of NaOH 0.1N followed 5 by extraction with ether (3×25 ml). The combined organic phases are washed with brine (25 ml) dried over MgSO₄ anhydride which is then filtered of

ooled etheral filtrate is saturated with a stre (g) resulting in the formation of a heavy precianticipated carbamate) which is collected by washed with dry ether (20 ml) and dried to weight in a desiccator under high vacuum (0. over KOH pellets

The compounds of the invention e.g. in fr salt form can be utilized by formulating one them in compositions such as tablets, capsule for oral administration or in sterile solutions sions for narenteral administration. A conmixture of compounds of formula (I) or phys acceptable salt(s) thereof is compounded with logically acceptable vehicle, carrier, excipie preservative, stabilizer, flavor, etc., in a u form as called for by accepted pharmaceutics The amount of active substance in these coor preparations is such that a suitable dosage i Illustrative of the adjuvants which may b rated in tablets, capsules and the like are the a binder such as gum tragacanth, acacia, con gelatin: an excinient such as dicalcium ph disintegrating agent such as corn starch, pot alginic acid and the like; a lubricant such as 1 stearate; a sweetening agent such as sucrose, saccharin; a flavoring agent such as pepperr wintergreen or cherry. When the dosage un cansule, it may contain in addition to mater above type a liquid carrier such as a fatty o other materials may be present as coatings of wise modify the physical form of the dosag instance, tablets may be coated with shellar both. A syrup or elixir may contain the ac-

pound, sucrose as a sweetening agent, methyl and pro-pyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavour.

Sterile compositions for injection can be formulated 45 according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection. Buffers, preservatives, antioxidants and the like can be incorporated as required. Preferred antioxidants for use with the compounds of

the present invention include sodium metabisulphite and ascorbic acid.

While the invention will now be described in connection with certain preferred embodiments in the follow- 55 ing examples, it will be understood that it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by 60 the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars described are by way of example and for purposes of illustrative discussion of pre- 65 ferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description

tual aspects of the invention

EXAMPLE 1 0.5 g (3.03 mmole) of a-m-hydroxyphenylethyldimethylamine are dissolved in 15 ml of dry acetonitrile and 0.70 g (5.2 mmole) of diethylcarbamoylchloride are

Rosin (Ex. 1008):

The compounds of the invention e.g. in free form or 15 salt form can be utilized by formulating one or more of them in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration.

causes a beavy precipitation. The product is titlered off washed with ether and dried in a desiccator over KOH pellets. The carbamate is obtained as a white powder 800 mg (75%) mp. 177*-179* C. and identified as Nethyl-3[1-(dimethylamino)ethyl]phenyl carbamate having the formula

The compounds of the present invention are useful as pharmaceuticals. In particular they show the following activities in vitro and in vivo in the tests specified be

The values are correct when taken in comparison with the standard drug physostigmine.

> IN VITRO EXPERIMENTS Tests for anticholinesterase activity

A solubilized preparation of acetylcholinesterase was prepared from mouse whole brain (minus cerebellum). The brain was homogenized with (100 mg/ml) phos-

> Noven Ex. 1008 Page 5 of 8

- -

Rosin Discloses Use Of Antioxidants In Sterile Compositions For Injection Only As Required

Paper 25 at 25

stir at ambient temperature for 15-24 hours. Re-availthe acetonitrile under reduced pressure (20 followed by the addition of water (10-25 mi). the aqueous solution is adjusted to pH=11 b by estimation of the appropriate amount of NaOH 0.11 b by estimation with ether (3×25 mi). The organic phases are washed with brine (25 mi) formed ow MgSQu anhydride which is then filtered of cooled etheral filtrate is saturated with a stee (g) resulting in the formation of a heavy prec anticipated carbanate) which is collected by washed with dry ether (20 mi) and dried i weight in a descator under high vacuum (0

over KOH pellets The compounds of the invention e.g. in fr salt form can be utilized by formulating one them in compositions such as tablets, capsule for oral administration or in sterile solution sions for narenteral administration. A conmixture of compounds of formula (I) or phys acceptable salt(s) thereof is compounded wit logically acceptable vehicle, carrier, excipie preservative, stabilizer, flavor, etc., in a u orm as called for by accepted pharmaceutic The amount of active substance in these co or preparations is such that a suitable dosage Illustrative of the adjuvants which may rated in tablets, capsules and the like are the a binder such as gum tragacanth, acacia, cor relating an excinient such as dicalcium ph disintegrating agent such as corn starch, por alginic acid and the like; a lubricant such as stearate; a sweetening agent such as sucrose saccharin; a flavoring agent such as pepper wintergreen or cherry. When the dosage un cansule, it may contain in addition to mate above type a liquid carrier such as a fatty of other materials may be present as coatings wise modify the physical form of the dosag instance, tablets may be coated with shella both. A syrup or elixir may contain the a pound, sucrose as a sweetening agent, meth pyl parabens as preservatives, a dye and such as cherry or orange flavour. Sterile compositions for injection can be

Sterile compositions for injection can be according to conventional pharmaceutical dissolving or suspending the active substanc cle such as water for injection. Buffers, pr antioxidants and the like can be incorporate quired.

Preferred antioxidants for use with the compounds of the present invention include sodium metabisulphite and ascorbic acid.

While the invention will now be described in connection with certain preferred embodiments in the follow-55 ing examples, it will be understood that it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by 50 the appended claims. Thus, the following examples which include preferred embodiments way of example and for purposes of illustrative discussion of pre-65 ferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readful y understood description

Rosin (Ex. 1008):

4,948,807

Sterile compositions for injection can be formulated 45 according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection. Buffers, preservatives, antioxidants and the like can be incorporated as required.

Preferred antioxidants for use with the compounds of the present invention include sodium metabisulphite and ascorbic acid.

The compounds of the present invention are useful as pharmaceuticals. In particular they show the following activities in vitro and in vivo in the tests specified be-

The values are correct when taken in comparison with the standard drug physostigmine.

IN VITRO EXPERIMENTS Tests for anticholinesterase activity

A solubilized preparation of acetylcholinesterase was prepared from mouse whole brain (minus cerebellum). The brain was homogenized with (100 mg/ml) phos-

> Noven Ex. 1008 Page 5 of 8

Ex. 1008 at 7:45-53; Ex. 2012 at ¶¶ 64-67

Enz Confirms That Rosin Does Not Suggest An Oxidative Degradation Problem For RA₇

Paper 25 at 26-27

The racemic mixture (±)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in form of its hydrochloride is known from the European patent application 193,926 where it is identified as RA7 HCl.

the optically active centre, is mainly responsible for the acetylcholinesterase inhibiting activity of the phenyl carbamates.

- 2 -

Enz (Ex. 1002): n of its hydrochloride is known tion 193,926 where it is

100-7041

3-[(1-dimethylamino)ethyl]-

The compounds according to the invention have never been specifically disclosed in the literature. The free base may be prepared from the racemate by separation of the enantiomers in accordance with known methods, e.g. using di-0,0'-p-toluyltartaric acid. The acid addition salts may be prepared from the free base in known manner. These include e.g. the hydrogen tartarte.

> Noven Ex. 1002 Page 3 of 23

Rosin Discloses Millions Of "Compounds Of The Invention"

Paper 25 at 24-25

Rosin (Ex. 1008):

4,948,807

be given tog

There is :

cerbating th

carbamates malian brain

activity, e.g.

Thus acc

provided a p duce antich

system of

general for

R . is had

Especial

been descr

tuted deriv

Re=CH1

30

35

45


Accordin

suffering fr

tics and ger stay of patie There is a (3) Bisquaternary structures, e.g. Demacarium, Amenonium. These agents tend to be more selective abibitors of acetylcholinesterase than butyrylse, compared nary molecules The pharmaceutical application of the quaternary

tive, or due anticholinesterase agents is limited because of their poor side effects netration through cell membranes. They are therenation and fore used for actions outside the central nervous system. with narcot and are usually given parenterally, since they are not reliably absorbed from the gastrointestinal tract. Edrotency. phonium, neostigmine and pyridostigmine and the bisbe given t quaternary analogues are used in anesthetic practice for which have the reversal of the action of muscle relaxants. They are diminish or also used for the treatment of myasthenia gravis, and paralytic ileus. Physostigmine is the only potent anti-cholinesterase surprisingly

agent which has been used clinically to treat conditions in which an elevation of brain acetylcholine activity is desired. These include, Alzheimer's disease, tardive dyskinesia, Down's syndrome and Huntingdon's chorea. Physostigmine is also used to reverse the effects of overdose of anticholinergic agents, anti-Parkinson drugs, benzodiazepines and opiate analgesica. ostigmine is a natural alkaloid extracted from 25 alabar beans and the seeds of the vine Physostigma




There is a need to provide new carbamate derivatives which show greater chemical stability than physostig-

40	zyl,
	R ₂ is hyd
	R1 and R
	are atta
45	cal,
	R ₃ is hyd
	R4 and R
	lower a
	the me
50	or a pharm
	physiologic:
	these comp

should be significantly higher than those of physostigmine and that the incidence and severity of side effects tions bavin should be less than those of physostigmine at therapeunervous sys tic doses. alkyl group both methy

- There is also a need to provide new compounds which can be given orally or parenterally to treat chronic conditions in which it is desired to raise cholin-Certain c 60 have previo ergic activity in the central nervous system. These incompound R5=methy clude, Alzheimer's disease, Down's syndrome, Hun-tingdon's chorea, Friedrich's ataxia. to be an in There is also a need to provide compounds that can drops. The
- be given parenterally at the end of operations, and anes- 65 R3 are met thetic procedures, to restore wakefulness, respiration and cardiovascular parameters to normal, after the use cholinergic, opiates, benzodiazepines, neu

Thus according to the present invention there is now provided a pharmaceutical composition adapted to produce anticholinesterase activity in the central nervous system of mammals comprising a compound of the 25 general formula I



Hereinafter these compounds are called compounds of the invention.

Ŧ


wherein

- R1 is hydrogen, lower alkyl, cyclohexyl, allyl or benzyl,
 - R₂ is hydrogen, methyl, ethyl or propyl, or
 - R_1 and R_2 together with the nitrogen to which they are attached form a morpholino or piperidino radical,
 - R₃ is hydrogen or lower alkyl,
 - R4 and R5 are the same dr different and each is a lower alkyl, and the dialkylaminoalkyl group is in the meta, ortho or para position,
- 50 or a pharmacologically acceptable salt thereof and a physiologically acceptable carrier therefor. Hereinafter these compounds are called compounds of the invention.

Ex. 1008 at 4:21-53; Ex. 2012 at ¶ 63

The "Compounds Of The Present Invention" Are The Large Class Of Eight Million-Plus Compounds

Paper 42 at 7-8; see also Paper 25 at 24-25 & n.4



Ex. 2058 at 18, 31; Ex. 1049 at 35:23-36:19, 37:16-39:5

Neither Rosin Nor Elmalem Discloses Transdermals

Paper 42 at 13; Paper 44 at 12-13; see also Paper 25 at 3-4, 27, 36

Dr. Kydoi	nieus (Ex. 1025):
16	Q. Okay. It does not <mark>the '807 patent does</mark>
17	not discuss transdermal formulations; right?
18	A. <mark>No,</mark> it does not discuss.
17	Q. And <mark>Elmalem did not prepare any</mark>
18	transdermal formulations; right?
19	A. <mark>Right.</mark>

Ex. 1025 at 249:16-18, 257:17-19; see also Ex. 1025 at 186:6-10; Ex. 1049 at 39:15-25

Whether Rivastigmine Undergoes Oxidative Degradation Is Formulation-Specific

Paper 25 at 4, 13, 27, 35-36

Dr. Schöneich (Ex. 1025):

24	Q. And you agree with the general principle
1	that the extent of degradation depends on the
2	chemical environment in which a drug is
3	formulated?
4	A. So if you have a drug which is susceptible
5	to degradation, the extent to which it actually
6	happens, that depends on the environment.

Ex. 1025 at 95:24-96:6; see also Ex. 2012 at ¶ 49

Whether Rivastigmine Undergoes Oxidative Degradation Is Formulation-Specific

Paper 25 at 4, 13, 27, 35-36

Dr. Kydonieus (Ex. 1025):

8	Q. So if you have oxidative degradation in a
9	solution, you cannot conclude that it would also
10	be a problem, for instance, in a transdermal
11	<pre>patch; right?</pre>
12	A. I said that many times. That is
13	formulation dependent.

Ex. 1025 at 258:8-13; see also Ex. 2012 at ¶ 49

Dosage Form Can Determine Whether An Antioxidant Is Required

Paper 44 at 12-13; see also Paper 25 at 13

Dr. Schöneich (Ex. 1048):

3	Q And it's your opinion that the
4	dosage form is significant? That's what you
5	say in the first line of 48; is that right?
6	A Yes.
21	Q And my question was whether or not
22	the dosage form that is selected can
23	determine whether or not an antioxidant is
24	required.
25	MR. GLYNN: Objection to form.
2	Q It's your opinion that it could;
3	correct?
4	MR. GLYNN: Objection to form.
5	Also, compound question.
6	A The formulation, if you if you
7	say the formulation is equivalent to the
8	dosage form, it can make a difference, so,
9	yes.
10	Q It can make a difference whether or
11	not an antioxidant is required?
12	A Yes.

Ex. 1048 at 70:3-6, 70:21-71:12; see also Ex. 2012 at ¶ 49

Hydrolysis Of Carbamates Had Been Studied Experimentally Since The 1930s

Paper 25 at 31-32; Paper 44 at 13

Dr. Schöneich (Ex. 1048):


17	Q	And you would agree with me that
18	the hydr	olysis of monomethyl carbamates has
19	been sti	died experimentally since the 1930s?
20	А	That's what Dr. Klibanov states.
21	Q	And you don't dispute that, do you?
22	А	I don't dispute it.
23	Q	And you <mark>also don't dispute that the</mark>
24	hydrolys	is of dialkyl carbamates has been
25	studied	experimentally since the 1930s?
2	A	Yes.

Ex. 1048 at 25:17-26:2; Ex. 2012 at ¶¶ 78, 81-82, 84-96

Mechanisms Of Hydrolysis Of Carbamates Had Been Experimentally Determined As Of 1998

Paper 25 at 31-32; Paper 44 at 13


Dr. Schöneich (Ex. 1048):



Ex. 1048 at 26:11-20; Ex. 2012 at ¶¶ 78, 81-82, 84-96

Oxidative Mechanisms Were Poorly Understood As Of 1998

Paper 25 at 18



Ex. 2014 at 7; Ex. 1015 at 3; Ex. 2012 at ¶ 121

Testing Was Required To Determine Intrinsic Stability

Paper 25 at 19

Dr. Kydonieus (Ex. 1010):

Indeed,

regulatory guidelines in effect as of January 1998 recommended that applicants perform stability tests on the drug substance and drug product. This included stress testing on the drug substance to determine its intrinsic stability and degradation pathways, as well as formal studies on the drug substance to show that it will remain within specification during the re-test period if stored under the recommended storage conditions. (See ICH Topic Q 1 A, Stability Testing Guidelines: Stability Testing of New Drug Substances and Products (CPMP/ICH/380/95) (Ex. 1014).)

Bond Strengths Do Not Indicate The Conditions Under Which A Radical Will Form

Paper 44 at 1; see also Paper 25 at 16

Dr. Schöneich (Ex. 1048):

6	Q And if you turn back to paragraph
7	nine.
8	A Yes.
9	Q And you also discuss there relative
10	radical stabilities; correct?
11	MR. GLYNN: Objection to form.
12	A What we see in this table, which is
13	on page five, paragraph nine, first of all,
14	on the right-hand column, absolute values,
15	these are bond dissociation energies which
16	are measured, and just for comparison, in the
17	middle column, they are radical relative
18	radical stabilities.
19	Q So, you are saying that methane is
20	relatively less stable than the C-H bond to a
21	tertiary carbon (CH3)3CH?
22	A So, the carbon-hydrogen bond in
23	methane is stronger than the carbon-hydrogen
24	bond in the tertiary in the tertiary
25	carbon-hydrogen

2	Q And that is a relative assessment;
3	correct?
4	MR. GLYNN: Objection to form.
5	A It's a relative assessment within
6	this group of compounds. But there are
7	certainly absolute numbers to support that.
8	Q And those numbers don't tell us
9	under what conditions the radicals were
10	formed, do they?
11	A These numbers are absolute values
12	of bond dissociation energies, so, they
13	should be independent of the measurement.
14	These are absolute numbers.
15	Q But they don't tell me under what
16	conditions the radical will form, do they?
17	MR. GLYNN: Objection to form.
18	A The bond dissociation energy is
19	just by its mere fact a bond dissociation
20	energy. It does not tell you under which
21	conditions you form radicals in any chemical
22	reaction.

Ex. 1048 at 22:6-23:22

Testing Is Required To Determine Whether Rivastigmine Oxidative Degrades Under Pharmaceutically Relevant Conditions Paper 25 at 2, 13-14, 16, 19-20, 22, 23, 27, 35-36, 42

Dr. Schöneich (Ex. 1025):

10	Q. So whether rivastigmine oxidatively
11	degrades in a specific formulation is something
12	that has to be shown?
13	A. Well, whether rivastigmine is susceptible
14	to degradation that can be deduced from the
15	structure, whether it actually happens, that
16	needs to be shown experimentally and the extent
17	to what it happens needs to be shown
18	experimentally.
18	experimentally.

Ex. 1025 at 96:10-18

Testing Is Required To Determine Whether Rivastigmine Oxidative Degrades Under Pharmaceutically Relevant Conditions Paper 25 at 2, 13-14, 16, 22, 23, 27, 35-36, 42

Dr. Kydonieus (Ex. 1025):

6	Q. So let me go back to my question. Just
7	knowing that a compound as you put it is
8	susceptible to oxidation doesn't tell you how
9	much oxidative degradation will occur over any
10	<pre>particular time; right?</pre>
11	A. Over any particular time? It doesn't tell
12	you how much degradation you will get period
13	depending on that formulation.

Dextromethorphan Is "Especially Susceptible" To Oxidative Degradation But "Very Stable"

Paper 25 at 17; Paper 44 at 2-4

Carey & Sundberg (Ex. 1007):

 Benzylic positions are "especially susceptible" to oxidation

Dr. Schöneich's opinion (Exs. 1011, 1032):


- "Dextromethorphan Was Known To Be Susceptible To Oxidation"
- Dextromethorphan was "prone to oxidation"

The prior art teaches (Exs. 2050, 2051):

- Dextromethorphan is "very stable"
- Dextromethorphan is "stable under all normal conditions of storage"
- Dextromethorphan has "excellent stability" under pharmaceutically relevant conditions

Drugs With Structural Features Of Rivastigmine Were Not Reported To Undergo Oxidation

Paper 25 at 18



Ex. 2022 at 68, 73, 75, 77, 78, 82, 92; Ex. 2012 at ¶¶ 132-34

Dr. Schöneich Provided No Evidence To Show Dr. Klibanov's Real-World Pharmaceuticals Were Unstable

Paper 44 at 5-6; Paper 25 at 18

Dr. Schöneich (Ex. 1048):

13	Q That wasn't my question. I was
14	asking you about <mark>whether you had done any</mark>
15	literature searches relating to any of the
16	five compounds, real world examples, that
17	Dr. Klibanov relied on saying that they
18	undergo oxidative degradation in any
19	formulation.
20	MR. GLYNN: Objection to form.
21	A I have not done literature research
22	to that respect.

Dr. Schöneich Provided No Evidence To Show Dr. Klibanov's Real-World Pharmaceuticals Were Unstable

Paper 44 at 5-6; see also Paper 25 at 18

Dr. Schöneich (Ex. 1048):

5	Q	Okay. And you have a testing lab
6	at Kansas	, don't you?
7	A	I have a laboratory, yes.
8	Q	Okay. And <mark>that lab could have run</mark>
9	some test:	s on any one of these drugs to
10	determine	whether or not they undergo
11	oxidative	degradation under a certain set of
12	condition	s; correct?
13	A	Well, <mark>certainly we have the</mark>
14	capacity,	but we haven't done it.
15	Q	You chose not to do that; correct?
16	A	We chose not to do that.

Ex. 1048 at 50:5-16; see also Ex. 2012 at ¶¶ 132-34

PDR Reports Chemical Instability Of Nicotine

Paper 44 at 8; see also Paper 25 at 17-18

Physicians' Desk Reference (Ex. 2022):

Nicotine has a characteris-

tic pungent odor and turns brown on exposure to air or light.

coasted tableta of 5 mg each or as supposterions of 10 mg each. Bach tableta de contains acateging, acetytated monoglycenide, corresalts wax, collabase sociate phthalase, corre storch, DAC Bod Nr, 20 Januarum Iake, DUC Yellow Nr, 6 Usuminum iron oxide, kathin, Instane, magnetism storator, withylpar- ator, pharmaenciaid glazo, sylphitylane glyco, posidone, propylparaben, acitum benzate, soritata monobiate, sur- orces, table, timinum dioxide, and white wax. Each supposi- tores, pharmaenciaid glazo, and white wax. Each supposi- tores, table, timinum dioxide, and white wax. Each supposi-		Dr. S	chöneich	(Ex. 1048):
tory also contains hydrogenated vagetable oil. Tableta and suppositorises contain less than 0.2 mg software unit and are thus directically software from. INDICATIONS AND USAGE For the relief of accessional constipation and irregularity. For two as a part of a lowed cloaxing regimme in groupering the patient for surgery or for proparing the software coins for x-ray ando acopic examination. Dataloas will not require the cloanic	HOW SUPPLIED Duclotax, brand of bisacodyl, is supplied as either light orange enteric cased tablets of 5 mg such in sample park- ages of 2 or bores of 4, 10, 25, 50, 100 (OTC as well as hospital uit dosed and 1000, or as argumentaries of 10 mg each in sample packages of 1 m bors of 4, 8, 15, 50, and 500. NIC 0097 4800 itables!	13	Q	And <mark>"turns brown on exposure to</mark>
	NDC 0074500 isopositorinal Score Duclosta Labelat and suppositorins at temperatures below TPI (20°C). Avoid execusive humidity. Duclosta is also supplied in a Bowel Prey Kit. Each kit con- tains one Duclosta suppository (10 mgl, four Duclosta tablets is mg sach, and complete patient instructions. BIBLIOGRAPHY	14	<mark>air"</mark> is a	reference to the oxidation of
Stimulant institutes, such as Dulcolata, are contraindicated for patients with acute surgical abdomas, appendicitiz, rec- tal blaceling, patterentoritis, or instatinal obstruction. WARNINGS AND PRECAUTIONS Use of Dairobax is not recommended when abdominal pain, neurose, or vomilitar are invest. Loss term administration	Roth, VW, et al. "Pharmackinetics and Lanstive Effect of Biascely1 after: Administration of Varieus Deages Perms"; Armeins-Forsch. 391D, No. 4, pp. 570–6 (1988). Additional illereiture references available upon requast. Shourn in Product Identification Guide, page 508	15	nicotine?	
of Duloitas in not recommended in the treatment of chronic constiputor. This protect head in the sund head of T days unless deemed recomment, and the days are may include a subset in constraint of the subset of the subset of condition. If this occurs, the patient should discontinue use These products include and the subset out of the reach of children. Preparaty Category B	HADITROL® B (viscoline transformal system) Systemic delivery of 21, 14, or 7 mg/day over 24 hours Prescribing Information DESCRIPTION		A	It implies oxidation.
Twinking Reproduction studies of oral doses of Datoetax biascodyll have born performed in rata administered up to 70 times the human down, and have revealed to ovidenci of upstried fer- tility or damage to the from. At the dose which expands to 87 lither survival at warning. There are, however, on adequate add well controlled studies in pregnant women, hence Dato- tax Anothe bund driving perspectively and discretion of	Bahiroli a transformal system that provides systemic delivery of noticeal following it a splitation to instatishin for 2h Johns. providiant rain, in a colorest-expansion of a pyroline and a 1 pyrolinian rain, in a colorest-expansion y evileor. Testy water- molube, strongly alkaline, oily, volatile, hyprococycle liquid obtanced from the boacco paint. Nicolas has a charateris- dic pumper soler and turns hown on sequences to air for light. Is do more arreaded from in blocks. The free faklandi is in the more arreaded from in blocks.	10	Q	So, but a person of ordinary skill
the physician. Extent of Grag Absorption In a phormacokinetic (crossover) study involving 12 patients Robot, 1980, planna level at 6 tonotody were measured [6- too 6 mg Daiolast tablets, and following vertal administra- tion of one 50 mg Daiolast tablets, and following vertal administra- tion of one 50 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and following vertal administra- tion of one 70 mg Daiolast tablets, and table	absolute rightly through the skin and metatory text. Restarted Parks $\left(\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \right) \\ \end{array} \right) = \left(\begin{array}{c} \begin{array}{c} \\ \end{array} \right) \\ \end{array} \right) = \left(\begin{array}{c} \begin{array}{c} \\ \end{array} \right) \\ \end{array} \right) = \left(\begin{array}{c} \end{array} \right) \\ \end{array} \\ \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	13	<mark>in the art</mark>	would understand that to be a
Salaring mont precover eve.	Chemical Name: S41:methyl-Apyraldinyl) pyridiae Molecular Pownada: C ₂ B ₁ /N ₂ Molecular Weight: 162.23 Iniziation Constants pK ₁ =7.24, pK ₂ =3.04 Octanol-Water Partilion Coefficient: 151 at pH 7 Habitro systems are round, flat, 0.6-mm-thick multi-layer units containing mothers as the active agent. Proceeding	14	reference	to oxidative instability of
Institive may result in some abdominal disconfort. OVERDOSAGE There are no specific antidotes that are required to be admin- istered in the sweat of overdosage, however, supportive care may be required in order to prevent debyteristion and/or elec- trolyte imbalance. DOSAGE AND ADMINISTRATION	units containing alcodies as the active agent. Proceeding from the visible arriante forward the northex attached to the stress-entries in the stress stress of the stress stress of the stress-entries activate a showing (3) a layer containing a methorpic acid copymers polition is minitime disponded in a short in compassion to (2) alove; (1) a groaterities allowing and the procession with overlaps the short or layer and must be removed prior to use.	15	nicotine;	correct?
Adulta and children 12 years of age and over: Take 2 or 3 tablets (anually 2) in a single dose once daily information will be noverseded by supplements and subsequent edition	system are pharmacologically inactive.	16	A	A POSA would certainly see this as
÷		17	a warning	that nicotine would undergo
		18	oxidation.	

Ex. 2022 at 27, 46; Ex. 1048 at 54:12-58:18

There Are Reasons Other Than Oxidative Instability To Select A Dry Dosage Form

Paper 44 at 11; see also Paper 25 at 18

Dr. Schöneich (Ex. 1048):

21	Q Well, just generally speaking,
22	there are reasons to select a dry dosage form
23	other than chemical instability?
24	A Well, the mode of application. If
25	you want to give a tablet, it's a dry dosage
2	form, yeah.
3	Q Yes. So there are other reasons.
4	A Okay.
5	Q Do you agree?
6	A But that doesn't exclude the
7	oxidation sensitivity as a problem.
8	Q I understand that, but just taking
9	this one step at a time. Okay. There are
10	reasons other than chemical stability for
11	selecting a dry dosage form; correct?
12	A Let me think a moment.
13	I would say predominantly dry
14	dosage forms are selected if you have

15	chemically unstable molecules, but, okay,
16	there could be some other reasons.
17	Q Well, how about convenience to the
18	patient of taking a dry dosage form, such as
19	a tablet?
20	A Yeah, that could be. I said that,
21	yeah.
22	Q And what about reasons other than
23	oxidative instability? There are reasons
24	strike that.
25	There are reasons other than
2	oxidative instability for selecting a dry
3	dosage form; correct?
4	A Yes.
5	Q And one of those would be, for
6	example, avoiding hydrolysis?
7	A For example.

Ex. 1048 at 71:21-73:7; see also Ex. 2012 at ¶ 134

The Salt Form Of A Drug May Undergo Oxidative Degradation

Paper 42 at 4-5; see also Paper 25 at 18

Dr. Kydonieus (Ex. 1049):

6	Q. And it's your opinion that the salt of
7	morphine needed to be mixed with an antioxidant
8	prior to use to prevent oxidative degradation,
9	correct?
10	A. Yes, there's saline first of all,
11	what that statement basically says that you have
12	to dissolve it. I mean, you cannot inject a
13	crystal into a person or an animal. You can
14	cause thrombosis and whatever else, so you have
15	to dissolve it, and you dissolve it and you know
16	that morphine is susceptible to oxidation. You
17	would use saline plus an antioxidant.

18	Q. So <mark>even though it's a salt, you would</mark>
19	still use an antioxidant, correct?
20	MR. COULSON: Objection.
21	A. Okay, I will give you my opinion, my
22	extensive opinion my extensive experience.
23	Salts are always better than the bases. Not
24	always. Again, never always. 95 percent of the
25	time, as far as oxidation is concerned, are
2	better than the base. But that does not mean,
3	necessarily, that the salt does not degrade. It
4	degrades to a lesser extent most of the time,
5	but it doesn't mean that it will not degrade.

Formulation In A Dry Dosage Form Does Not Indicate The Real-World Pharmaceuticals Are Susceptible To Oxidation

Paper 44 at 11; see also Paper 25 at 18

Petitioners' Response (Paper 52):

Response to p. 11 ¶¶ 1-2: Patent Owners mischaracterize Dr. Schöneich's

testimony. Patent Owners incorrectly assert that Dr. Schöneich testified that

formulation of a compound in a dry dosage form establishes that is susceptible to

oxidation or that measures were taken to avoid oxidation. Dr. Schöneich testified

that the so-called "real world examples" selected by Dr. Klibanov from the PDR

were formulated as a dry dosage form, as a salt, or both. (Ex. 1032 ¶ 47.)

Whether Rivastigmine Would Degrade In An Acrylic Adhesive Could Not Be Reasonably Predicted From Its Structure

Paper 25 at 42

Dr. Kydonieus (Ex. 1025):

12	Q. Could you turn to your deposition, Page
13	89?
14	Let's put it on the screen. It will
15	be easier. Page 89, and 18, Line 18. And you
16	were asked the question: "So am I right that
17	it's your opinion that when rivastigmine's in an
18	acrylic adhesive, it will not necessarily undergo
19	oxidative degradation?
20	"Answer: I don't know the answer."
21	A. Absolutely correct. Yes.
22	Q. Now, Dr. Kydonieus
23	A. May I finish. It is formulation
24	dependent.

Ex. 1025 at 283:12-24; see also Ex. 2012 at ¶ 156 & n.17

Enz Discloses Rivastigmine In An Acrylic Adhesive Without Requiring An Antioxidant

Paper 25 at 43

Enz (1002):

EXAMPLE 2: Preparation of a tran a hydrophilic polymen

- 14

EXAMPLE 2: Preparation of a transdermal composition containing a hydrophilic polymer

Composition

Compound of formula I', e.g. comp Hydrophilic polymer, e.g. Eudragi Non svellable acrylate polymer, e Plasticizer, e.g. Brij 97***

- * : Registered Trade Mark, avai
 W. Germany
- ** : Registered Trade Mark, avai
 Zutphen, Netherlands
 ***: Registered Trade Mark, avai

W. Germany

The components are added to acete appropriate volatile organic solv mass. The mass is spread on top c (thickness 23 microns) using a cc a film of thickness 0.2 mm when v at room temperature over 4 to 6 b cut up into patches about 10 sq c

Composition

*

Compound of formula I', e.g. compound A	20	%
Hydrophilic polymer, e.g. Eudragit E 100*	30	%
Non swellable <mark>acrylate polymer</mark> , e.g. Durotack 280 – 2416**	44	%
Plasticizer, e.g. Brij 97***	6	%

- : Registered Trade Mark, available from Röhm, Darmstadt, W. Germany
- ** : Registered Trade Mark, available from Delft National Chemie
 Zutphen, Netherlands
- ***: Registered Trade Mark, available from Atlas Chemie,
 - W. Germany

A POSA Would Not Believe That All Amines Break Down In Acrylic Adhesives Based On Two Amines In Sasaki

Paper 25 at 41-42

	(43) Pub Num Num	(19) Japa (12) Kokai Unexamin I Open Patent Applicat lication Date her of Claims her of Pages mination Request	ed Pate		office (JP) plication Bu	1 59-1 Octo 1 3 not
51)	Int. Cl. ³ I A61K 9/70 //A61K 31/355	dentification Code	Intern 7057-	al File 4C	No.	
(54)	Acrylic Plaster					
(21)	Application No.:	58-57689		(72)	Inventor:	5
(22)	Application Date:	March 31, 1983		(71)	Applicant:	
(72)	Inventor:	SASAKI, Hiroaki Nitto Electric Industry C 1-1-2 Shimohodumi, Ibaraki-shi HORIUCHI, Tetsuo	Co., Ltd.	(74)	Agent:	F
	SPE 1. Title of the Inventi Acrylic Plaster 2. Claims	CIFICATION		pla pre	paration, in w ster comprising paration in wi ster comprising	an a
1	by blending at least o	Ihesive plaster character one tocopherol selected plaster comprising an ac acited in claim (1), where	from srylic	ten pre	stored for a li dency for the paration to akdown and dia Here, it is po	e th be ssiper

Sasaki (Ex. 1005):

Here, it is possible to prevent the dissipation and photodecomposition of the drug by way of sealing and light shielding with aluminum laminate packaging or the like, but with drugs blended with a plaster comprising an adhesive substance as described above, and especially phenolic hydroxyl group-containing compounds, amine compounds and the like, breakdown of the drug will still proceed, even with aluminum laminate packaging, and there are more than a few drugs that cannot withstand usage involving storage for two to three years.


156. The disclosure in Sasaki of just two amine-containing compounds in

one prototype transdermal formulation would not have taught or suggested to a

POSA that all amine-containing compounds break down in any acrylic adhesive.¹⁷

Rivastigmine


Paper 25 at 17



Ex. 1001 at 1:8-15; Ex. 2012 at ¶¶ 80, 96 n.8, 145

Amine-Containing Drugs Were Not Reported To Contain Antioxidants In Commercial Formulations

Paper 25 at 42



Ex. 2022 at 32, 36, 68, 73, 75, 77, 82; Ex. 2012 at ¶¶ 132-35, 157

Amine Or Phenolic Hydroxyl Compounds In An Acrylic Adhesive Were Not Reported To Contain An Antioxidant Paper 25 at 42-43 & n.11

Physicians' Desk Reference (Ex. 2022):

The Climara® system comprises two layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent polyethylene film, and (2) an acrylate adhesive matrix containing estradiol USP.


The Vivelle system comprises three layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent flexible film consisting of an ethylene vinyl alcohol copolymer film, a polyurethane film, urethane polymer and epoxy resin, (2) an adhesive formulation containing estradiol, acrylic adhesive, polyisobutylene, ethylene vinyl acetate copolymer, 1,3 butylene glycol,

Att

Habitrol systems are round, flat, 0.6-mm-thick multi-layer units containing nicotine as the active agent. Proceeding from the visible surface toward the surface attached to the skin are: (1) a tan-colored aluminized backing film; (2) a pressure-sensitive acrylate adhesive; (3) a layer containing a methacrylic acid copolymer solution of nicotine dispersed in a pad of nonwoven viscose and cotton;

other conju for 5 to 10 ye mL) 9 results in 11 was demons

IPR2014-0055



<1

3 5 3 4 8

Body and several sever

"Susceptibility" Does Not Indicate Whether Rivastigmine Will Undergo Any Oxidative Degradation

Paper 42 at 4; see also Paper 25 at 13, 16

Dr. Kydonieus (Ex. 1031):

10. Of course, whether rivastigmine would actually undergo oxidative

degradation in a particular pharmaceutical formulation depends on the specific

formulation. This is why, for a particular formulation, a POSA would conduct

testing to confirm to what extent, if any, the drug in the formulation oxidatively

degrades.

Ebert Discloses An Unconventional Method

Paper 25 at 37-38

Dr. Klibanov (Ex. 2012):

169. Ebert discloses a *non-conventional* method for manufacturing

transdermal devices containing "volatile or heat-sensitive drugs, enhancers or other

components cannot be subjected to drying or heating, such as would occur in an oven." (Ex. 1006, Ebert at 5, ll. 16-21.)

171. To address such nicotine-specific problems, Ebert discloses a method of manufacturing transdermal devices wherein an "active gel" of nicotine, BHT (thus notably in contradiction to Sasaki), and hydroxypropyl cellulose (HPC) is prepared by stirring for an "extended period of time." (*Id.* at 19, 1. 34-20, 1. 3.) In Example 1, nicotine was mixed with HPC for 26.5 hours in air, thereby amply exposing nicotine to air. (*Id.* at 20, 11. 10-12.) The active gel is then extruded onto an adhesive layer. (*Id.* at 1, 11. 13-20.)

Rivastigmine Transdermal Can Be Prepared Using Conventional Methods

Paper 25 at 37-38

Enz (Ex. 1002): tion (19) GB (11) 2 203 040(13). (43) Application published 12 Oct 1983

The present invention furthermore provides a pharmaceutical composition comprising a compound according to the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner.

The active agents may be administered in any conventional liquid or solid transdermal pharmaceutical composition

mass. The mass is spread on top of an aluminised polyester foil (thickness 23 microns) using a conventional apparatus, to produce a film of thickness 0.2 mm when wet.

Respectfully submitted,

Dated: May 26, 2015

<u>/s/ Raymond R. Mandra</u> Raymond R. Mandra Registration No. 34,382 FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104-3800

CERTIFICATE OF SERVICE

I certify that a copy of the foregoing PATENT OWNERS' DEMONSTRATIVE EXHIBITS PURSUANT TO 37 C.F.R. § 42.70(b) were served on May 26, 2015 by causing them to be sent by email to counsel for Petitioners at the following email addresses:

Steven J. Lee (slee@kenyon.com)

Michael K. Levy (mlevy@kenyon.com)

Chris Coulson (ccoulson@kenyon.com)

Joseph M. Reisman (BoxMylan2@knobbe.com)

Jay R. Deshmukh (BoxMylan2@knobbe.com)

William R. Zimmerman (BoxMylan@knobbe.com)

Dated: May 26, 2015

<u>/s/ Raymond R. Mandra</u> Raymond R. Mandra Registration No. 34,382 FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104-3800 Tel. 212-218-2100